Duchenne Muscular Dystrophy — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook.
Moriyama Hidenori et al. — RNA biology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42324661/
- 2.
Reply to the Letter of Editor addressed by D.M. Sati et al., about our article entitled "Radiosensitivity and Delayed Radiation-Induced Nucleo-shuttling of the ATM Protein in Fibroblasts from Duchenne Muscular Dystrophy Expressing Residual Dystrophin".
Foray Nicolas et al. — Journal of the neurological sciences (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42102643/
- 3.
Comment on "Radiosensitivity and delayed radiation-induced nucleo-shuttling of the ATM protein in fibroblasts from Duchenne muscular dystrophy expressing residual dystrophin".
Sati Deepti M et al. — Journal of the neurological sciences (15 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42107324/
- 4.
Optical Genome Mapping and Long-Read Sequencing Identifies a Novel Dystrophin Gene Inversion in a Patient With Duchenne Muscular Dystrophy.
Gallagher Ryan et al. — American journal of medical genetics. Part A (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41869909/
- 5.
The central role of macrophages in skeletal muscle regeneration: Phenotypic Polarization, metabolic reprogramming, and therapeutic prospects.
Liu Ruiqi et al. — Biochemical pharmacology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42069229/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Recruiting — Phase 2 — Satellos Bioscience, Inc.
https://clinicaltrials.gov/study/NCT07287189
- 2.
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Recruiting — Phase 3 — Solid Biosciences Inc.
https://clinicaltrials.gov/study/NCT07160634
- 3.
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Recruiting — Phase 2 — NS Pharma, Inc.
https://clinicaltrials.gov/study/NCT05996003
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a genetic condition causing progressive muscle weakness, mainly affecting boys. It is caused by a missing protein called dystrophin. Research into gene therapy and other treatments has advanced rapidly in recent years.
Most Recent Research
Duchenne muscular dystrophy (DMD) is a fatal X-linked recessive disorder caused by dystrophin deficiency. Antisense oligonucleotide (ASO)-mediated exon skipping has emerged as a cornerstone of DMD therapy to restore dystrophin expression. This review provides a comprehensive overview of the four FDA-approved ASO therapies - eteplirsen, golodirsen, viltolarsen, and casimersen - tracing their journey from pivotal clinical trials to post-marketing updates. While the development and clinical evaluation of these agents have established a pioneering framework for rare genetic diseases, they have also highlighted critical challenges. These include complexities in clinical trial design, discrepancies between preclinical efficacy and clinical outcomes, real-world burdens, and limited patient eligibility. Furthermore, the FDA's accelerated approval of these therapies based on limited clinical data remains a subject of ongoing debate. Confirmatory trials to verify clinical efficacy and long-term follow-up studies are actively underway. Concurrently, intensive research is focused on developing next-generation ASOs to achieve enhanced therapeutic efficacy and definitive clinical outcomes. Elucidating the trajectory of research and development in this field offers profound insights for shaping future therapeutic strategies in rare diseases.
Common Questions
What is Duchenne Muscular Dystrophy?
Duchenne muscular dystrophy is a genetic condition causing progressive muscle weakness, mainly affecting boys. It is caused by a missing protein called dystrophin. Research into gene therapy and other treatments has advanced rapidly in recent years.
How many clinical trials are available for Duchenne Muscular Dystrophy?
RareWays currently indexes 348 clinical trials for Duchenne Muscular Dystrophy, of which 69 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Duchenne Muscular Dystrophy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Duchenne Muscular Dystrophy.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.